Halobetasol Propionate (Page 2 of 2)

ADVERSE REACTIONS

In controlled clinical trials, the most frequent adverse events reported for Halobetasol Propionate Ointment included stinging or burning in 1.6% of the patients. Less frequently reported adverse reactions were pustulation, erythema, skin atrophy, leukoderma, acne, itching, secondary infection, telangiectasia, urticaria, dry skin, miliaria, paresthesia, and rash.


The following additional local adverse reactions are reported infrequently with topical corticosteroids, and they may occur more frequently with high potency corticosteroids, such as Halobetasol Propionate Ointment. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.


To report SUSPECTED ADVERSE REACTIONS , contact Teligent Pharma, Inc. at 1-856-697-1441,
or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Topically applied Halobetasol Propionate Ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

DOSAGE AND ADMINISTRATION


Apply a thin layer of Halobetasol Propionate Ointment to the affected skin once or twice daily, as directed by your physician, and rub in gently and completely.


Halobetasol Propionate Ointment is a super-high potency topical corticosteroid; therefore, treatment should be limited to two weeks, and amounts greater than 50 g/wk should not be used. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.


Halobetasol Propionate Ointment should not be used with occlusive dressings.

HOW SUPPLIED

Halobetasol Propionate Ointment, 0.05% is supplied in the following tube sizes:
50 g (NDC 70512-033-50)


Manufactured by:
Sola Pharmaceuticals

Baton Rouge, LA 70809


Revised: 01/2019

STORAGE

Store Halobetasol Propionate Ointment between 15°C and 30°C (59°F and 86°F)

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

NDC 70512-033-50


Halobetasol Propionate
Ointment, 0.05%


For topical use only.
Not for use in eyes.


Net Wt. 50 g
Rx Only

Sola Pharmaceuticals

Tube
(click image for full-size original)
carton
(click image for full-size original)

HALOBETASOL PROPIONATE halobetasol propionate ointment ointment
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70512-033
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HALOBETASOL PROPIONATE (HALOBETASOL) HALOBETASOL PROPIONATE 0.5 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
ALUMINUM STEARATE
PETROLATUM
PROPYLENE GLYCOL
ALLYL PENTAERYTHRITOL
SORBITAN SESQUIOLEATE
MONOSTEARYL CITRATE
YELLOW WAX
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:70512-033-50 1 TUBE in 1 CARTON contains a TUBE
1 50 g in 1 TUBE This package is contained within the CARTON (70512-033-50)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA209978 02/04/2019
Labeler — Sola Pharmaceuticals (080121345)

Revised: 01/2021 Sola Pharmaceuticals

Page 2 of 2 1 2

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.